effect, a patient may erroneously believe a drug is helpful when it is not. This is especially true of addictive, mind-altering drugs like marijuana. A marijuana withdrawal syndrome occurs, consisting of anxiety, depression, sleep and appetite disturbances, irritability, tremors, diaphoresis, nausea, muscle convulsions, and restlessness. Often, persons using marijuana erroneously believe that the drug is helping them combat these symptoms without realizing that actually marijuana is the cause of these effects. Therefore, when a patient anecdotally reports a drug to have medicinal value, this must be followed by objective scientific studies." The US Drug Enforcement Administration also says: Arguments for medical uses of prohibited drugs Most of the psychoactive drugs now prohibited in modern societies have had medical uses in history. In natural plant drugs like opium, coca, cannabis, mescaline, and psilocybin, the medical history usually dates back thousands of years and through a variety of cultures. Psychedelics such as LSD and psilocybin (the main ingredient in most hallucinogenic mushrooms) are the subject of renewed research interest because of their therapeutic potential. They could ease a variety of difficult-to-treat mental illnesses, such as chronic depression, post-traumatic stress disorder, and alcohol dependency. In 2018, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation for psilocybin-assisted therapy for treatment-resistant major depressive disorder. In 2019, the FDA also granted breakthrough therapy designation for psilocybin therapy treating major depressive disorder more generally. MDMA (Ecstasy) has been used for cognitive enhancement in people with Parkinson's disease, and has shown potential in treating posttraumatic stress disorder, social anxiety, and alcohol addiction. Lack of access to controlled medications Under prohibition, millions of people find it very difficult to obtain controlled medications, particularly opiate pain-relievers. The United Nations 1961 Single Convention on Narcotic Drugs requires that opiates be distributed only by medical prescription, but this is impractical in many areas. According to the Transnational Institute, June 2008: According to the International Narcotics Control Board (INCB) and the World Health Organisation (WHO) there is now an unmet demand in opiates. Ironically, the current drug control regulations hamper access to controlled opiate medications for therapeutic use. Many patients are unable to access morphine, methadone or an equivalent opioid. Global medical morphine consumption would rise five times if countries would make morphine available at the level of the calculated need, according to a recent WHO estimate. According to the New York Times, September 2007: Under Sierra Leone law,